肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性

2019-04-22 不详 MedSci原创

口服PD-L1抑制剂PD-L1单抗Durvalumab
关注

Maxinovel Pharmaceuticals是一家专注于开发免疫肿瘤治疗和靶向治疗药物的生物技术公司。它利用其口服免疫肿瘤产品平台，为全球患者提供多组分有效组合的单个口服避孕药片剂。

Maxinovel Pharmaceuticals是一家专注于开发肿瘤免疫治疗和靶向治疗药物的生物技术公司。它利用其口服免疫肿瘤产品平台，为全球患者提供多组分有效组合的口服避孕药片剂。

Maxinovel Pharmaceuticals在2019年AACR上展示了其口服活性小分子PD-L1抑制剂与市售的PD-L1抗体药物Durvalumab，在人PD-L1敲入的MC38细胞和人PD-1敲入的小鼠模型中做了头对头比较实验。两次测试实验均证明，这两种分子表现出类似的肿瘤生长抑制活性（TGI）。

纽约大学医学临床副教授Zujun Li博士评论："这一结果非常令人兴奋，口服活性小分子PD-L1抑制剂具有与PD-L1单抗Durvalumab类似的功效。我们期待将口服活性药物添加到现今的抗体治疗中。"

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-05-13 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2020-01-04 LSJ119

    #PD－L1抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-12-13 yhj-time

    #口服PD-L1抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2020-01-23 mxj1971624

    #novel#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-09-20 snf701207

    #mAb#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-04-24 smartjoy

    #PD-L1#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1851978, encodeId=9efe18519e81d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 13 13:52:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656463, encodeId=39551656463ce, content=<a href='/topic/show?id=14001392e65' target=_blank style='color:#2F92EE;'>#PD－L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13927, encryptionId=14001392e65, topicName=PD－L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5eb24855327, createdName=LSJ119, createdTime=Sat Jan 04 21:52:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755482, encodeId=03e91e554828e, content=<a href='/topic/show?id=c02c38198fe' target=_blank style='color:#2F92EE;'>#口服PD-L1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38198, encryptionId=c02c38198fe, topicName=口服PD-L1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24c36916622, createdName=yhj-time, createdTime=Fri Dec 13 21:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755551, encodeId=5e951e55551ae, content=<a href='/topic/show?id=760e1298301' target=_blank style='color:#2F92EE;'>#novel#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12983, encryptionId=760e1298301, topicName=novel)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347536955924, createdName=mxj1971624, createdTime=Thu Jan 23 10:52:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912124, encodeId=a28f1912124f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 20 22:52:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Wed Apr 24 09:52:00 CST 2019, time=2019-04-24, status=1, ipAttribution=)]
    2019-04-24 ylz8407

    #PD-L1单抗#

    0